ÇѸ²´ëÇб³¼º½Éº´¿ø

±èÇö¾Æ ±³¼ö

  • Áø·á°ú ·ù¸¶Æ¼½º³»°ú

Àü¹®Áø·áºÐ¾ß

·ù¸¶Æ¼½º°üÀý¿°, º£Ã¼Æ®º´, ·çǪ½º, °­Á÷¼ºÃ´Ãß¿°, Åëdz, ½¦±×·»ÁõÈıº

ÀüÈ­ ¿¹¾à 1577-1801
±³¼ö´Ô»çÁø

(ÁÖ°£) Áø·á½Ã°£Ç¥ (2025-12-15 ~ 2025-12-20)

Áø·á½Ã°£Ç¥
Áø·á½Ã°£ ¿ù È­ ¼ö ¸ñ ±Ý Åä
¿ÀÀü ÈÞÁøÈÞÁø
¿ÀÈÄ ÈÞÁø
±³¼ö´Ô »çÁø

±âº»Á¤º¸

ÇзÂ

ÇзÂ

1995.03 ~ 1998.08¼­¿ï´ëÇб³ Àǰú´ëÇпø ÀÇÇйڻç

1992.03 ~ 1994.02¼­¿ï´ëÇб³ Àǰú´ëÇпø ÀÇÇм®»ç

1983.03 ~ 1989.02¼­¿ï´ëÇб³ Àǰú´ëÇÐ ÀÇÇÐÇлç

°æ·Â

°æ·Â

1997.07 ~ 2000.02¼­¿ï´ëÇб³º´¿ø ¿Ü·¡±³¼ö

1996.03 ~ 1997.06Case Western Reserve University Research sicentist

1994.03 ~ 1996.02¼­¿ï´ëÇб³º´¿ø ÀüÀÓÀÇ

1990.03 ~ 1994.02¼­¿ï´ëÇк´¿ø Àü°øÀÇ ¼ö·á

ÇÐȸȰµ¿

ÇÐȸȰµ¿

´ëÇѳ»°úÇÐȸ Á¤Ã¥ À§¿ø

´ëÇѳ»°úÇÐȸ º¸ÇèÀ§¿ø

´ëÇѳ»°úÇÐȸ °£ÇàÀ§¿ø

´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ º¸ÇèÀÌ»ç

´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ ±¹Á¦ÀÌ»ç

´ëÇÑ·ù¸¶Æ¼½ºÇÐȸÁ¤È¸¿ø

³í¹®

Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study (ARTHRITIS RESEARCH & THERAPY)

Osteoarthritis, What and What Not to Treat (INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES)

Psychotropic Drug Use in Korean Patients With Osteoarthritis (JOURNAL OF KOREAN MEDICAL SCIENCE)

Enhancement of Intracellular Cholesterol Efflux in Chondrocytes Leading to Alleviation of Osteoarthritis Progression (Arthritis and Rheumatology)

ISG15 is involved in chondrogenic differentiation through activation of IFN-¥ã signaling (BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS)

Interferon-gamma signaling promotes cartilage regeneration after injury (SCIENTIFIC REPORTS)

Korean guidelines for the management of gout (KOREAN JOURNAL OF INTERNAL MEDICINE)

A CAUSATIVE ROLE FOR PERIARTICULAR SKELETAL MUSCLE WEAKNESS IN THE PROGRESSION OF JOINT DAMAGE AND PAIN IN OA (ANNALS OF THE RHEUMATIC DISEASES)

A common variant rs2054564 in ADAMST17 is associated with susceptibility to lumbar spondylosis (SCIENTIFIC REPORTS)

Temporal Change in the Use of Laboratory and Imaging Tests in One Week Before Death, 2006-2015 (JOURNAL OF KOREAN MEDICAL SCIENCE)
·ù¸¶Æ¼½ºÇÐ (±ºÀÚÃâÆÇ»ç)

Á×À½ÇÐ ±³½Ç (ÇÏ¿ø¹Ìµð¾î)

ÀÇ»çèâÀü : ´ëÇѹα¹¿¡¼­ ÀÇ»ç·Î »ê´Ù´Â °Í (Çã¿øºÏ½º : Çã¿ø¹Ìµð¾î)

Á×À½À» ¹è¿ì´Â ½Ã°£ (âºñ)